Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab
Hari S. Raman(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Austin Kim(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Cynthia K. Hahn(Boston University), Caron A. Jacobson(Dana-Farber Cancer Institute), Mark A. Murakami(Harvard University), Erin M. Parry(Broad Institute), Amy Bessnow(Harvard University), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), David E. Fisher(Massachusetts General Hospital), David Qualls(Memorial Sloan Kettering Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Aswin Sekar(Dana-Farber Cancer Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), Eric Jacobsen(Dana-Farber Cancer Institute), Robert Redd(Harvard University)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k